Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by Extended Half-life (EHL) therapies in the 2010s, which enabled reduced dosing frequency and improved patient outcomes.
HEMLIBRA’s Continued Dominance in Hemophilia A
The hemophilia A market has historically been fragmented, but this changed with the launch of HEMLIBRA in 2017. Approved first in the US, followed by Europe and Japan, HEMLIBRA, a bispecifi...
